IBSA USA
Temi Aladesuru currently serves as the Manager of Business Development & New Product Planning at IBSA USA since November 2022. Prior experience includes a role as a Manager of Business Development at Daiichi Sankyo, where Temi engaged in various functional areas through a rotational program, including Global Business Development and Market Research. Prior positions include an Intramural Coordinator and Supervisor at Princeton University, where Temi managed staff and supervised sports activities, as well as an Independent Researcher at the Center for Disease Dynamics, Economics & Policy. Temi also worked as an Innovation Associate at Georgetown University, focusing on diversity in medical school admissions. Temi earned a Bachelor of Arts in Ecology and Evolutionary Biology from Princeton University in 2019.
This person is not in any teams
IBSA USA
IBSA USA is the subsidiary of IBSA Group, the largest privately owned pharmaceutical company in Switzerland. IBSA is committed to improving patient quality of life through research, innovation, and the development of effective drugs and cutting-edge technologies. IBSA USA markets two unique levothyroxine formulations in the U.S. for the treatment of hypothyroidism: Tirosint® (levothyroxine sodium) capsules and Tirosint®-SOL (levothyroxine sodium) oral solution. IBSA also markets Licart™ (diclofenac epolamine) topical system 1.3%, the only once-a-day topical nonsteroidal anti-inflammatory (NSAID) available in the U.S. to treat acute pain due to minor strains, sprains, and contusions. IBSA is focused on the health and well-being of patients and driven by the desire to bring therapeutic alternatives to as many people as possible. IBSA Group bases its philosophy on four sustainable pillars: Person, Innovation, Quality, and Responsibility. For more information about Tirosint, Tirosint-SOL, or Licart, including Full Prescribing Information, go to each brand’s respective website.